Volume 18
Issue 2 October

Article 3

In the Wireless Era: Leadless Pacing
Kathy Lee
Chu-Pak Lau

Follow this and additional works at: https://www.jhkcc.com.hk/journal

Recommended Citation
Kathy Lee, Chu-Pak Lau, In the Wireless Era: Leadless Pacing Journal of the Hong Kong College of Cardiology
2010;18(2) https://doi.org/10.55503/2790-6744.1069
This Review Article is brought to you for free and open access by Journal of the Hong Kong College of Cardiology. It has been
accepted for inclusion in Journal of the Hong Kong College of Cardiology by an authorized editor of Journal of the Hong Kong
College of Cardiology.

In the Wireless Era: Leadless Pacing
KATHY LF LEE AND CHU-PAK LAU
From Department of Medicine, Queen Mary Hospital, Hong Kong
LEE AND LAU: In the Wireless Era: Leadless Pacing. Cardiac pacemakers have been the standard therapy for
patients with bradyarrhythmias for several decades. The pacing lead is an integral part of the system that serves as
a conduit for delivery of energy pulses to stimulate the myocardium. However, it is also an Achilles tendon that
directly causes most device complications both acutely during implant and chronically years afterwards. Both durability
and optimization of stimulation site are important areas of improvement for manufacturers and implanters. Elimination
of the pacing lead and utilization of other means for energy transfer is the only way to avoid lead complications and
allow better choice of stimulation site. Leadless pacing with ultrasound-mediated energy has been demonstrated in
animals and humans in acute studies. This has aroused intense interest in the field of cardiac pacing. With concerted
effort from the profession and the industry, leadless pacing may indeed become a sound idea. (J HK Coll Cardiol
2010;18:53-58)
Cardiac resynchronization therapy, Heart failure, Pacemaker, Ultrasound

Introduction
All pacing leads are associated with
complications like infection, fracture, failure and
dislodgment. Lead extraction is a high risk procedure.
With new device systems that often require implantation
of multiple leads, and with patients living longer, the
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incidence of lead complications becomes compounded
over time. 1 Therefore, there is a strong demand to
develop a pacing system that eliminates the pacing lead
as a conduit for energy transfer. Randomized clinical
trials on cardiac resynchronization therapy have
demonstrated its clinical benefits. Access to the left
ventricle is achieved with the use of a pacing lead to be
advanced into the coronary sinus and positioned in a
coronary vein branch. Implantation of this lead is
technically demanding and associated with a significant
incidence of failure to implant, implantation in a
suboptimal location, and complications.2,3 Comparing
to epicardial pacing, endocardial left ventricular
stimulation that minimizes the conduction delay from
the epicardium to the endocardium may be more
physiological and therefore give rise to greater
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hemodynamic benefits.4,5 Leadless pacing will enable
endocardial left ventricular stimulation without the risks
of systemic thromboembolism and mitral regurgitation.
It will also avoid diaphragmatic stimulation, avoid right
ventricular apical pacing, enable multi-site pacing, and
allow almost free choice of stimulation location within
the left or right ventricle. It may also address challenges
in pediatric pacing, and development of a truly MRIcompatible pacing system.

Acoustic Energy for Leadless Pacing
Many concepts have been patented for the
development of a leadless pacing system. Having a long
history and wide application in medical technology,
ultrasound energy is considered safe and was chosen
to prove the concept of energy transfer. The use of
ultrasound-mediated energy to drive a remotely
positioned electrode for direct myocardial stimulation
is the first to be reported in the medical literature. This
new technology uses the mechanical-to-electrical
properties of piezoelectric materials for transformation
of energy. The experimental set-up include: an
ultrasound transmitting transducer connected
to an ultrasound generator, a steerable bipolar
electrophysiology catheter incorporating a receiverelectrode at the distal tip. Ultrasound energy was
amplitude-adjusted and transmitted at around 330 kHz.
The lower frequency used in this application achieves
better tissue penetration. Ultrasound pulses generated
from the transmitting transducer traveled through the
chest wall to reach the receiver-electrode with circuitry
to transform the pulses into electrical energy for
myocardial stimulation. The feasibility and safety of
this novel technology was first demonstrated acutely in
animals. 6 In the acute safety study, histological
examination was performed in pigs that were exposed
to continuous ultrasound transmission from the
investigational system for two hours. No mechanical or
thermal bio-effect was identified in the sacrificed
animals. In the acute feasibility study, the receiverelectrode incorporated into a transvascular catheter was
selective positioned and in contact with various heart
chambers of a pig. An external transmitter was then
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placed on the chest wall of the animal, with acoustic
gel used for coupling. Ultrasound energy was then
transmitted through the chest to the receiver, the acoustic
energy was converted to electrical energy, and the
electrodes contacting endocardium stimulated pacing.
The electrode catheter was a modified steerable bipolar
EP catheter with receiver-transducers incorporated near
the tip between the bipolar pacing electrodes. Proximal
connections on the catheter allowed either direct
electrical pacing using a Pacing System Analyzer or
monitoring of the receiver output during ultrasoundmediated pacing. The catheter itself was not directly
involved in or required for ultrasound-mediated pacing.
The acute porcine study demonstrated feasibility of
leadless ultrasound-mediated pacing in five animals at
30 selected sites in the right atrium, right ventricle, left
ventricle, and simultaneously in both left and right
ventricles.6
Following the animal experiments, human studies
were performed. 7 Twenty-four patients were tested
during or after completion of clinical electrophysiology
procedures (Figure 1). A total of 80 pacing sites in the
right atrium, right ventricle, and left ventricle
were tested. The transmit-to-receive distance was
11.3±3.2 cm. Ultrasound-mediated pacing was achieved
at all 80 sites with consistent capture at 77 sites. There
was no adverse event related to ultrasound-mediated
pacing. No patient experienced discomfort during
pacing. This novel technology targeting cardiac
resynchronization therapy was also tested in heart failure
patients.8 In these patients, the acoustic window on the
chest wall that allows efficient ultrasound transmission
was defined and found to be large and sufficient for
subcutaneous implantation of the ultrasound generator,
even after accommodating changes with respiratory
movement and body positioning (Figure 2).
Incorporating this novel technology, the future
implantable leadless pacing system is being designed.
The system includes an ultrasound generator to be
implanted subcutaneously in the acoustic window of
the chest wall and an endocardial receiver-electrode.
The receiver electrode is delivered by a steerable
transvascular catheter to the target heart chamber, and
be detached and implanted onto the endocardium
directly. The receiver and transmitter are programmed
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PSA=pacing system analyzer
Figure 1. Equipment set up of the first study of leadless pacing in humans.

Figure 2. Acoustic window outlined on a reconstruction CT thorax.
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to operate at the same frequency of ultrasound pulses
to avoid external interference. The ultrasound beam will
be optimized and focused onto the receiver electrode in
order to improve the efficacy of energy transfer. The
estimated device longevity will need to be comparable
to that of a conventional pacemaker to make it
commercially viable. The acoustic window suitable for
implant on the patient's chest wall can be localized
preoperatively by conventional echocardiography, a
convenient method that has been shown to predict
efficient ultrasound transmission for leadless pacing.8
There are of course other unresolved issues that
ongoing research is aiming to answer (Table 1).9,10 For
example, many will doubt the long term safety of
continuous ultrasound exposure. Although the lack of
effect of short term ultrasound-mediated pacing has been
shown histologically in animal experiments, tissue
injury secondary to heating with continuous exposure
is theoretically possible. Similar studies on long term
exposure when ultrasound energy was applied in
continuous pacing will address the safety concern.
Another challenge of this technology is environmental
interference which may be ubiquitous. Although precise
formatting and fine tuning of the device can be done,
little is known about its actual performance in the real
world. This is another big safety issue that requires
extensive evaluation. Apart from energy delivery,

transmission of sensed endocardial electrograms is an
important function of a pacing lead. There is so far no
available information on how the sensing circuit of the
future leadless pacemaker is going to operate. As for
the risk of infection, the receiver electrode is small,
embedded in the endocardial followed by complete
endothelialization. It is expected to carry minimal risk
of infection, probably comparable to that of coronary
stents and atrial septal defect occluders.

Alternative Energy Sources
Apart from ultrasound, an alternating magnetic
energy source has been tested in a pig model for leadless
cardiac stimulation. 11 The system consists of two
components, an external transmitter unit and a receiver
unit in contact with the myocardium. The subcutaneous
primary coil generates an alternating magnetic field,
which is converted by the secondary coil inside the heart
to a voltage pulse for pacing stimulation. In the pig
experiment described, an alternating magnetic field of
approximately 0.5 mT was generated by the transmitter
unit in a distance of 3 cm. Voltage pulses with a duration
of 0.4 ms and voltage amplitude of 0.6-1.0 V were
generated. Continuous stimulation of the heart was
demonstrated for 30 minutes. The advantage of this

Table 1. Challenges in the development of leadless pacing technology
• Low efficiency of energy conversion significantly shortens battery longevity
• Problem with consistent capture with a constantly changing pacing window
• Long term safety of prolonged exposure to ultrasound with possible heating effect and tissue injury
• Reliability of a leadless sensing circuit
• Operation and integration of multiple sensing and pacing sites for CRT
• Potential interference from external environment
• Unconventional parasternal site for implanting the pacemaker generator
• Development of a reliable delivery and anchoring system for implanting the endocardial receiver-electrode
• Integration with an implantable defibrillator
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technology is that the efficiency of energy conversion
is relatively high, making device longevity less of a
problem. However, the transmitter coil is of considerable
measurement, 60 mm in diameter, 10 mm in width, and
80 g in weight, while the receiver is 15 mm in length
and 2.5 mm in diameter. Apart from the size of the
device, one major concern of this technology is potential
external interference by environmental magnetic fields.
The long term safety with heat production in the receiver
unit generated with continuous exposure is also
uncertain.
Other wireless energy sources have been used for
stimulation to a limited extent. Radiofrequency energy
transmission is employed in an implantable microstimulator device currently under clinical investigation
for neuro-modulation applications. 12 However, the
implant incorporates a battery requiring frequent
recharging using an inductive link from an external
device. In general, the use of radiofrequency power for
wireless applications in the body has the disadvantages
of being unfocused and having a shallow depth of
penetration. Therefore, it is less efficient than ultrasound
energy. It also requires the transmitter and receiver to
be in close proximity, which essentially precludes its
use for many applications including cardiac pacing.
Ultrasound energy transduction is currently being
used in a clinical application of a wireless sensor.13 In
this application, the receiver is coupled to a pressure
transducer implanted within an abdominal aortic
aneurysm graft for post procedure monitoring after
endovascular repair. The transmitter is an external
device placed on the anterior abdomen to communicate
with the implanted receiver to acquire real time intrasac pressure data.

Future Perspectives
Leadless pacing with ultrasound-mediated energy
was demonstrated in animals and humans in acute
studies. This is by far the most advanced development
with proven technological feasibility. More scientific
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data will be collected from ongoing animal and human
research. With refinement of the technology, challenges
identified will be addressed. Currently, a prototype
device and the implantation equipment are being
developed, and clinical trial of the permanent
implantable system is being planned. At the same time,
various competing technologies are being developed and
evaluated. Although it is not certain if the intended
progress will be accomplished, the favorable result
achieved has aroused significant interest in the field of
cardiac pacing. Many including those in the device
industry are keen to be involved in the development of
a commercially viable leadless implantable pacemaker.
When this is materialized, lead complications and lead
extractions will be minimized.

Summary and Conclusions
Leadless pacing will also open up a new arena
for cardiac resynchronization therapy. Some nonresponders may be converted to responders with
optimization of the left ventricular stimulation site.
Multi-site pacing will no longer be limited by problems
in vascular access or coronary venous anatomy.
Responders may obtain maximal benefit from cardiac
resynchronization therapy with endocardial left
ventricular stimulation.
Although leadless pacing is only in the stage of
proof-of-concept, subcutaneous implantable
defibrillator has been developed and tested in clinical
trial. 14 The preliminary result is encouraging. The
integration of leadless pacemaker and subcutaneous
implantable defibrillator is important as heart failure
patients frequently require cardiac resynchronization
therapy in combination with an implantable defibrillator.
Despite all the advances achieved, much more
work needs to be done before we can accomplish this
major breakthrough in the development of leadless
implantable cardiac devices (Table 2). By that moment,
implanting a pacing lead will become a procedure of
history.
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Table 2. Key issues in development of leadless pacing
• Pacemaker lead complications and failures are important clinical problems.
• The indication of device therapy has been expanded with the advent of cardiac resynchronization therapy;
multiple pacing leads are now implanted in non-bradycardiac heart failure patients.
• Coronary vein anatomy may limit implant success and the clinical response to cardiac resynchronization
therapy. The benefit of cardiac resynchronization therapy may be maximized with endocardial selected-site
and multi-site pacing.
• The idea of energy transfer utilizing an external energy source to stimulate the heart directly was conceived as
the basis of leadless pacing.
• Leadless cardiac stimulation with ultrasound-mediated energy was demonstrated to be feasible in acute studies
in animal models, human patients and heart failure patients.
• Alternative technology of leadless cardiac stimulation with alternating magnetic field for energy induction has
also been successful in an animal experiment.
• The future leadless pacemaker consists of a subcutaneously implanted ultrasound transmitter and an
endocardially implanted receiver. A percutaneous catheter delivery and anchoring system will be used for the
implantation procedure.
• The challenges of leadless pacing include but are not limited to the efficacy of energy conversion, potential
external interference, sensing issues, and long term safety.
• A prototype device for leadless pacing with ultrasound energy has been developed for clinical testing. The first
human implant may be feasible in the near future.
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